Crossmark

Relatlimab, an Immune Checkpoint Inhibitor that Blocks LAG-3, the Latest Drug to be Added to the Arsenal of Systemic Therapies for Melanoma: What Does a Surgical Oncologist Need to Know?

Crossref DOI link: https://doi.org/10.1245/s10434-023-14416-0

Published Online: 2023-10-16

Published Print: 2024-01

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

van Akkooi, Alexander C. J. https://orcid.org/0000-0002-3262-6935
License Information

Text and Data Mining valid from 2023-10-16

Version of Record valid from 2023-10-16
More Information

Article History

Received: 2 August 2023

Accepted: 25 September 2023

First Online: 16 October 2023

Disclosures

: Alexander C.J. van Akkooi is a member of the Advisory Board for, and received consultancy honoraria from, Amgen, Bristol-Myers Squibb, Neracare, Novartis, MSD-Merck, Merck-Pfizer, Pierre Fabre, Provectus, Sanofi, Sirius Medical, and 4SC.

Free to read: This content has been made available to all.

Document is current

Any future updates will be listed below